Biotechnology Changing Frugal Eating Habits – How Novo Nordisk/Eli Lilly’s Weight Loss Drugs Reshaping Food Spending – Novo Nordisk (NYSE:NVO), Eli Lilly and Co (NYSE:LLY) Read more
Biotechnology Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025 – Eli Lilly and Co (NYSE:LLY) Read more
Biotechnology Eli Lilly Suffers Legal Loss For Its Popular Weight Loss/Diabetes Drug In Lawsuit Against Florida Compounding Pharmacy – Eli Lilly and Co (NYSE:LLY) Read more
Biotechnology Bristol Myers’ $14B Bet On Schizophrenia – Drug Cuts Symptoms Without Common Side Effect Of Weight Gain Associated With Other Antipsychotics – Bristol-Myers Squibb (NYSE:BMY) Read more
Biotechnology Elevance, CVS Health Are First Medicare Insurers To Cover Novo Nordisk’s Weight Loss Sensation Wegovy – CVS Health (NYSE:CVS), Novo Nordisk (NYSE:NVO), Elevance Health (NYSE:ELV) Read more
Biotechnology Is Eli Lilly Winning The War On Weight Loss Drugs? Zepbound Overtakes Wegovy In US Prescriptions – Novo Nordisk (NYSE:NVO), Eli Lilly and Co (NYSE:LLY) Read more
Biotechnology Oprah Winfrey Tackles Weight Loss Drug Stigma In Prime-Time Special Amid Wegovy-Ozempic Frenzy: ‘For 25 Years, Making Fun Of My Weight Was National Sport’ – Novo Nordisk (NYSE:NVO) Read more
Biotechnology US Prescriptions Race For Weight Loss Drugs – Eli Lilly’s Zepbound Overtakes Novo Nordisk’s Wegovy – Eli Lilly and Co (NYSE:LLY) Read more
Biotechnology Inconsistent Insurance Coverage For Weight Loss Drugs – Novo Nordisk’s GLP-1s Face Hurdles Despite Health Benefits – Novo Nordisk (NYSE:NVO) Read more